Download PDF
Thromb Haemost 1985; 54(03): 612-616
DOI: 10.1055/s-0038-1660081
Original Article
Schattauer GmbH Stuttgart

Platelet Aggregation in Whole Blood: The Role of Thromboxane A2 and Adenosine Diphosphate

A J Carter
The Department of Medicine, University Hospital, Queen’s Medical Centre, Nottingham, UK
,
S Heptinstall
The Department of Medicine, University Hospital, Queen’s Medical Centre, Nottingham, UK
› Author Affiliations
Further Information

Publication History

Received 09 April 1985

Accepted 05 July 1985

Publication Date:
19 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The platelet aggregation that occurred in whole blood in response to several aggregating agents (collagen, arachidonic acid, adenosine diphosphate, adrenaline and thrombin) was measured using an Ultra-Flo 100 Whole Blood Platelet Counter. The amounts of thromboxane B2 produced were measured by radioimmunoassay. The effects of various inhibitors of thromboxane synthesis and the effects of apyrase, an enzyme that destroys adenosine diphosphate, were determined.

Platelet aggregation was always accompanied by the production of thromboxane B2, and the amounts produced depended on the nature and concentration of the aggregating agent used. The various inhibitors of thromboxane synthesis - aspirin and flurbiprofen (cyclo-oxygenase inhibitors), BW755C (a cyclo-oxygenase and lipoxygenase inhibitor) and dazoxiben (a selective thromboxane synthase inhibitor) - did not markedly inhibit aggregation. Results obtained using apyrase showed that adenosine diphosphate contributed to the aggregation process, and that its role must be acknowledged when devising means of inhibiting platelet aggregation in vivo.

Keywords

Platelet aggregation - Thromboxane A2 - ADP
 

  • References

  • 1 Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behaviour in blood. J Pharmacol Methods 1980; 3: 135-158
    CrossrefPubMedGoogle Scholar
  • 2 Lumley P, Humphrey P PA. A method for quantitating platelet aggregation and analyzing drug-receptor interactions on platelets in whole blood in vitro. J Pharmacol Methods 1981; 6: 153-166
    CrossrefPubMedGoogle Scholar
  • 3 Fox SC, Burgess-Wilson M, Heptinstall S, Mitchell JR A. Platelet aggregation in whole blood determined using the Ultra-Flo 100 platelet counter. Thromb Haemostas 1982; 48: 327-329
    PubMedGoogle Scholar
  • 4 Gaarder A, Jonsen J, Laland S, Hellem A, Owren PA. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 531-532
    CrossrefPubMedGoogle Scholar
  • 5 Harrison M JG, Mitchell J RA. The influence of red blood-cells on platelet adhesiveness. Lancet 1966; 2: 1163-1164
    PubMedGoogle Scholar
  • 6 Benveniste J, Henson PM, Cochrane CG. Leukocyte-dependent histamine release from rabbit platelets. J Exp Med 1972; 136: 1356-1377
    CrossrefPubMedGoogle Scholar
  • 7 Blackwell GJ, Flower RJ, Russel-Smith N, Salmon JA, Thorogood PB, Vane JR. Prostacyclin is produced in whole blood. Br J Pharmacol 1978; 64: 436 P (Abstr.)
    PubMedGoogle Scholar
  • 8 Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature New Biology 1971; 231: 235-237
    CrossrefPubMedGoogle Scholar
  • 9 Cockbill SR, Heptinstall S, Taylor PM. A comparison of the abilities of acetylsalicylic acid, flurbiprofen and indomethacin to inhibit the release reaction and prostaglandin synthesis in human blood platelets. Br J Pharmacol 1979; 67: 73-78
    PubMedGoogle Scholar
  • 10 Randall MJ, Parry MJ, Hawkeswood E, Cross PE, Dickinson RP. UK-37, 248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity. Thromb Res 1981; 23: 145-162
    CrossrefPubMedGoogle Scholar
  • 11 Higgs GA, Flower RJ, Vane JR. A new approach to antiinflammatory drugs. Biochem Pharmacol 1979; 28: 1959-1961
    CrossrefPubMedGoogle Scholar
  • 12 Carter AJ, Bevan JA, Hanley SP, Morgan WE, Turner DR. A comparison of human pulmonary arterial and venous prostacyclin and thromboxane synthesis-effect of a thromboxane synthase inhibitor. Thromb Haemostas 1984; 51: 257-260
    PubMedGoogle Scholar
  • 13 Packham MA. Platelet function inhibitors. Thromb Haemostas 1983; 50: 610-619
    PubMedGoogle Scholar
  • 14 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-2998
    CrossrefPubMedGoogle Scholar
  • 15 Hamberg M, Samuelsson B. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc Natl Acad Sci USA 1974; 71: 3400-3404
    PubMedGoogle Scholar
  • 16 Borgeat P, Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: Effects of ionophore A23187. Proc Natl Acad Sci USA 1979; 76: 2148-2152
    CrossrefPubMedGoogle Scholar
  • 17 Radmark O, Malmsten C, Samuelsson B. The inhibitory effects of BW755C on arachidonic acid metabolism in human polymorphonuclear leukocytes. FEBS Letts 1980; 110: 213-215
    CrossrefPubMedGoogle Scholar
  • 18 Heptinstall S, Bevan J, Cockbill SR, Hanley SP, Parry MJ. Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. Thromb Res 1980; 20: 219-230
    CrossrefPubMedGoogle Scholar
  • 19 Defreyn G, Deckmyn H, Vermylen J. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2. Thromb Res 1982; 26: 389-400
    CrossrefPubMedGoogle Scholar
  • 20 Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-665
    CrossrefPubMedGoogle Scholar
  • 21 Kinlough-Rathbone RL, Packham MA, Reimers HJ, Cazenave JP, Mustard JF. Mechanisms of platelet shape change, aggregation, and release induced by collagen, thrombin, or A23, 187. J Lab Clin Med 1977; 90: 707-719
    PubMedGoogle Scholar
  • 22 Saniabadi AR, Lowe G DO, Barbenel JC, Forbes CD. A comparison of spontaneous platelet aggregation in whole blood with platelet rich plasma: Additional evidence for the role of ADP. Thromb Haemostas 1984; 51: 115-118
    PubMedGoogle Scholar
  • 23 O’Brien JR. Effects of salicylates on human platelets. Lancet 1968; 1: 779-783
    PubMedGoogle Scholar
  • 24 Weiss HJ, Aledort LM, Kochwa S. The effects of salicylates on the haemostatic properties of platelets in man. J Clin Invest 1968; 47: 2169-2180
    CrossrefPubMedGoogle Scholar
  • 25 Zucker MB, Peterson J. Inhibition of adenosine diphosphate-induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion. Proc Soc Exp Biol Med 1968; 127: 547-551
    CrossrefPubMedGoogle Scholar
  • 26 Nunn B. Comparison of the effects of aspirin in humans ex vivo in platelet-rich plasma and whole blood. Thromb Haemostas 1981; 46: 50 (Abstr.)
    PubMedGoogle Scholar
  • 27 Harrison M JG, Weisblatt E. A sex difference in the effect of aspirin on “spontaneous” platelet aggregation in whole blood. Thromb Haemostas 1983; 50: 773-774
    PubMedGoogle Scholar
  • 28 Niewiarowski S, Thomas DP. Platelet aggregation by ADP and thrombin. Nature 1966; 212: 1544-1547
    CrossrefPubMedGoogle Scholar
  • 29 O’Brien O. A comparison of platelet aggregation produced by seven compounds and a comparison of their inhibitors. J Clin Pathol 1964; 17: 275-281
    CrossrefPubMedGoogle Scholar
  • 30 Packham MA, Guccione MA, Chang PL, Mustard JF. Platelet aggregation and release: effects of low concentrations of thrombin or collagen. Am J Physiol 1973; 225: 38-47
    PubMedGoogle Scholar
  • 31 Silver MJ, Smith JB, Ingerman C, Kocsis JJ. Arachidonic acid-induced human platelet aggregation and prostaglandin formation. Prostaglandins 1973; 4: 863-875
    CrossrefPubMedGoogle Scholar
  • 32 Ardlie NG, Glew G, Schwartz CJ. Influence of catecholeamines on nucleotide-induced platelet aggregation. Nature 1966; 212: 415-417
    CrossrefPubMedGoogle Scholar
  • 33 Mills D CB, Roberts G CK. Effects of adrenaline on human blood platelets. J Physiol 1967; 193: 443-453
    CrossrefPubMedGoogle Scholar
  • 34 Zawilska K, Begent NA, Born G VR. Further evidence that haemostasis depends more on ADP than on thromboxane A2 . Thromb Haemostas 1983; 50: 340 (Abstr)
    PubMedGoogle Scholar